Core Insights - Angli康 (002940.SZ) reported its Q3 2025 results, revealing that as of October 24, 2025, nine institutional investors held a total of 94.36 million shares, representing 46.77% of the company's total equity [1] - The institutional holding percentage decreased by 7.00 percentage points compared to the previous quarter [1] Institutional Holdings - The institutional investors include Shenzhou JunTai Investment Co., Ltd., Zhejiang Angli康 Pharmaceutical Co., Ltd. - Phase I Employee Stock Ownership Plan, and several funds from major banks such as Bank of China, Industrial and Commercial Bank of China, and China Construction Bank [1] - The total institutional holding percentage is now at 46.77%, down from the previous quarter [1] Public Fund Holdings - Four public funds increased their holdings this period, including Huatai-PB Innovation Medicine Mixed A, GF Healthcare Stock A, and others, with an increase rate of 1.45% [2] - One public fund, China Europe Medical Health Mixed A, reported a decrease in holdings by 1.66% compared to the previous quarter [2] - One new public fund was disclosed this period, namely Longcheng Pharmaceutical Industry Selected Mixed Initiation A [2] - A total of 114 public funds were not disclosed this period, including notable funds like GF Technology Innovation Mixed A and others [2]
机构风向标 | 昂利康(002940)2025年三季度已披露前十大机构持股比例合计下跌7.00个百分点